Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News

  News Archive

Storm Therapeutics Raises £12M Series ‘A’ Funding
Tuesday, June 28, 2016
Storm Therapeutics has secured £12 million in series ‘A’ funding from Imperial Innovations, Cambridge Innovation Capital, Merck Ventures and Pfizer Venture Investments.

How Cancer Spreads in the Body
Monday, June 27, 2016
Cancer cells appear to depend on an unusual survival mechanism to spread around the body, according to an early study led by Queen Mary University of London.

Oxford Immunotec to Acquire Imugen
Monday, June 27, 2016
Oxford Immunotec has announced it has entered into a definitive agreement to acquire substantially all of the assets of Imugen, Inc. for $22.2 million in an all cash transaction expected to close on July 1, 2016.

Fix for 3-Billion-Year-Old Genetic Error
Monday, June 27, 2016
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.

“Amazing Protein Diversity” Discovered in Maize
Monday, June 27, 2016
The genome of the corn plant – or maize, as it’s called almost everywhere except the US – “is a lot more exciting” than scientists have previously believed. So says the lead scientist in a new effort to analyze and annotate the depth of the plant’s genetic resources.

Rosetta Genomics Receives Approval from New York State
Saturday, June 25, 2016
Company has received approval from the NY State for HEME FISH-based tests for detection of amplifications or rearrangements of DNA in a number of hematologic cancers.

Benson Hill, Danforth Plant Science Center Announce Partnership
Saturday, June 25, 2016
Partnership aims to create sustainable sources of bioenergy.

CRISPR Therapeutics Raises Series B Financing
Saturday, June 25, 2016
Funding to support the development of its CRISPR/Cas9 gene-editing platform and programs.

Savolitinib Global Phase II Trial Initiated in EGFR
Saturday, June 25, 2016
Company has announced the initiation of a Phase II expansion of the ongoing TATTON trial to evaluate the selective c-Met inhibitor savolitinib in EGFR mutant NSCLC.

<< 2 3 4 5 6 7 8 >>
Showing Results 41 - 50 of 33190
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!